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Abstract
Background: Hyperphosphatemia is associated with vascular calcification and bone mineral disorders and is a major
concern among patients with chronic kidney disease (CKD). However, the relationship between hyperphosphatemia
and renal outcome in non-CKD patients has not been studied. Furthermore, the clinical implications of
hyperphosphatemia in relation to the risks of acute kidney injury (AKI), end-stage renal disease (ESRD), and mortality
after hospitalization remain unresolved.
Methods: A total of 20,686 patients (aged ≥18 years) admitted to Seoul National University Bundang Hospital from
January 2013 to December 2013 were retrospectively reviewed. Patients were divided into quartiles according to
serum phosphorus level at the time of admission. The odds ratios (ORs) for AKI and hazard ratios (HRs) for ESRD and all-
cause mortality were calculated after adjustment of multiple covariates.
Results: AKI developed in 2319 patients (11.2%), with higher ORs for patients in the third and fourth quartiles (1.4
[1.24–1.68] and 2.8 [2.44–3.22], respectively) compared with the first quartile group. During a median follow-up period
of 4.0 years, 183 patients (0.88%) developed ESRD and 3675 patients (17.8%) died. Patients in the fourth quartile had
higher risks of ESRD and mortality than patients in the first quartile (HRs, 2.3 [1.46–3.75] and 1.4 [1.22–1.49],
respectively). These trends remained consistent in patients with an estimated glomerular filtration rate > 60ml/min/
1.73m2.
Conclusions: Hyperphosphatemia is related to the risks of AKI, ESRD, and mortality, and it may therefore be necessary
to monitor serum phosphorus level in hospitalized patients, irrespective of kidney function.
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Background
Chronic kidney disease (CKD) is increasingly recognized
as a public health problem [1] and is associated with
higher risks of cardiovascular disease and other condi-
tions, including infections and cancer [2]. Acute kidney
injury (AKI) is a renal complication that occurs in up to
20% of hospital admissions [3, 4], and which can eventu-
ally progression to CKD. Both AKI and CKD thus repre-
sent significant health burdens with potentially high
morbidity and mortality rates [5].
Serum phosphorus levels are regulated by multiple or-
gans including the kidney, bone, and digestive systems [6].
Given that the kidney plays a major role in phosphorus
regulation, phosphorus homeostasis can be disrupted in
patients with kidney disease. Abnormal phosphorus levels
may in turn be related to several morbidities, such as vas-
cular calcification, mineral bone disease, and hyperpara-
thyroidism [7, 8]. Furthermore, the risk of death has been
shown to increase by approximately 20% for each 1mg/dl
increment in serum phosphorus among patients with
CKD [9, 10]. Accordingly, the Kidney Disease Improving
Global Outcomes (KDIGO) guidelines recommend moni-
toring serum phosphorus levels and lowering elevated
levels towards the normal range in patients with CKD
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Age (years) 58.9 ± 17.0 61.4 ± 16.1 59.5 ± 16.7‡ 57.6 ± 17.1‡ 56.5 ± 18.1‡ < 0.001
Male sex (%) 52.5 57.4 55.2 50.6‡ 46.1‡ < 0.001
Body mass index (kg/m2) 23.7 ± 3.7 23.6 ± 3.7 23.8 ± 3.6 23.7 ± 3.6* 23.9 ± 3.9† 0.002
Comorbidities (%)
Hypertension 19.0 17.9 18.6 18.4 21.5‡ < 0.001
Diabetes mellitus 21.9 22.5 20.8 19.7† 24.5 < 0.001
History of cardiovascular disease 6.1 5.8 6.3 6.7 5.8 0.164
Chronic kidney disease 8.0 8.7 7.0* 7.0* 9.4 < 0.001
Medications (%)
ACEi 1.4 1.1 1.3 1.6 1.6 0.180
ARB 6.4 5.9 6.2 6.4 7.2* 0.040
Beta blocker 5.9 4.5 6.1† 6.2† 7.1‡ < 0.001
Calcium channel blocker 7.1 6.7 6.9 7.2 7.7* 0.193
Diuretics 5.3 5.2 4.9 4.6 6.4† 0.001
Laboratory findings
Hemoglobin (g/dL) 12.6 ± 2.1 12.3 ± 2.2 12.8 ± 2.0‡ 12.9 ± 2.0‡ 12.7 ± 2.2‡ < 0.001
Albumin (g/dL) 3.9 ± 0.6 3.7 ± 0.6 4.0 ± 0.6‡ 4.0 ± 0.5‡ 4.0 ± 0.6‡ < 0.001
Total cholesterol (mg/dL) 170.1 ± 47.5 157.3 ± 46.4 171.2 ± 43.8‡ 177.5 ± 47.3‡ 177.2 ± 50.0‡ < 0.001
Calcium (mg/dL) 8.6 ± 0.7 8.3 ± 0.7 8.7 ± 0.6‡ 8.8 ± 0.5‡ 8.8 ± 0.7‡ < 0.001
Phosphorus (mg/dL) 3.38 ± 0.81 2.46 ± 0.41‡ 3.21 ± 0.14‡ 3.64 ± 0.11‡ 4.38 ± 0.73‡ < 0.001
Creatinine (mg/dL) 0.82 ± 0.72 0.77 ± 0.42 0.76 ± 0.57 0.77 ± 0.44 1.00 ± 1.28‡ < 0.001
eGFR (mL/min/1.73 m2) 86.0 ± 35.5 88.9 ± 37.4 85.6 ± 36.8‡ 84.6 ± 30.2‡ 84.4 ± 36.2‡ < 0.001
Comparisons were evaluated using the Kruskal wallis test for categorical variables and analysis of variance for continuous variables (post-hoc analysis of least
significant difference between the two groups). The first quartile group served as a reference for the comparison between the two groups
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, eGFR estimated glomerular filtration rate
*P < 0.05; †P < 0.01; ‡P < 0.001, compared with the 1st quartile
Fig. 1 Non-linear relationship between serum phosphorus and predicted probability of acute kidney injury (AKI). Fitted line and 95% confidence
intervals indicated as solid and shaded areas, respectively
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[11]. Hyperphosphatemia was also recently shown to
increase the risk of cardiovascular disease in non-CKD pa-
tients [12, 13]. However, most studies of hyperphosphate-
mia have focused on certain disease subsets rather than
considering all hospitalized patients. Furthermore, the re-
lationship between hyperphosphatemia and AKI has not
yet been fully established. The present study thus assessed
the effects of hyperphosphatemia on the risks of AKI,




We retrospectively reviewed data for adult patients (aged
≥18 years) admitted to Seoul National University Bundang
Hospital in 2013 (n = 21,572). Patients without measure-
ments of serum phosphorus (n = 575) and/or with under-
lying ESRD (n = 311) were excluded. Consequently, a total
of 20,686 patients were included in the present analysis.
Data collection and definitions
The clinical parameters investigated were age, sex, body
mass index, hypertension, diabetes mellitus, history of
cardiovascular disease, CKD, and medications (including
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, β-blockers, calcium channel blockers,
and diuretics). Blood parameters including creatinine,
hemoglobin, cholesterol, calcium, phosphorus, and albu-
min were also examined. Estimated glomerular filtration
rate (eGFR) was calculated using the CKD Epidemiology
Collaboration equation [14].
Primary outcomes were the occurrences of AKI and
ESRD after hospital admission. AKI was defined ac-
cording to the KDIGO guideline [15] as meeting at
least one of the following criteria: increase in serum
creatinine by 0.3 mg/dl within 48 h or increase to 1.5
times baseline, known or presumed to occur within
the prior 7 days. Baseline creatinine was defined as
the lowest value measured < 90 days prior to admis-
sion. If this value was unavailable, the lowest creatin-
ine value measured between 90 and 180 days before
admission was used as the baseline. The events of
ESRD, such as dialysis and kidney transplantation,
were obtained from the Kidney Renal Registry data-
base of Korea. The additional patient outcome was
all-cause mortality following admission. The mortality
Table 2 Risk of acute kidney injury according to serum phosphorus level
Total eGFR < 60ml/min/1.73m2 eGFR ≥60ml/min/1.73m2
Groups OR (95% CI) P OR (95% CI) P OR (95% CI) P
Q1 1 (reference) 1 (reference) 1 (reference)
Q2 1.16 (1.004–1.340) 0.044 0.99 (0.657–1.480) 0.946 1.18 (1.012–1.383) 0.034
Q3 1.44 (1.237–1.684) < 0.001 1.38 (0.916–2.077) 0.124 1.41 (1.194–1.673) < 0.001
Q4 2.80 (2.435–3.222) < 0.001 2.64 (1.843–3.770) < 0.001 2.60 (2.226–3.038) < 0.001
eGFR estimated glomerular filtration rate, OR odds ratio, CI confidence interval
Fig. 2 Kaplan–Meier curves for end-stage renal disease (ESRD) according to quartiles of serum phosphorus
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data were obtained from the national database of Sta-
tistics Korea. All patients, except patients who were
death-censored, were followed up until July 2017.
Statistical analysis
Statistical analyses were performed using SPSS (version
23.0; IBM Corp., Chicago, IL, USA) and STATA (version
12.0; Stata Corp LP, College Station, TX, USA) softwares.
Continuous and categorical variables were expressed as
the means ± standard deviations and the proportions, re-
spectively. Categorical variables were compared by χ2
tests. Continuous variables were compared by an analysis
of variance or a post-hoc analysis of least significant differ-
ence, based on the number of comparison groups. Non-
linear relationships were evaluated using a restricted cubic
spline analysis. Odds ratios (ORs) with 95% confidence in-
tervals for the risk of AKI were calculated by a logistic re-
gression, with and without adjustment for the covariates,
such as age, sex, body mass index, hypertension, diabetes
mellitus, history of cardiovascular disease, medications,
eGFR, calcium, hemoglobin, cholesterol, and albumin
levels. The relationships between serum phosphorus and
ESRD or all-cause mortality were assessed using a Cox
proportional hazard ratio (HR) model before and after ad-
justment for covariates (i.e., AKI plus the above covari-
ates). The relationships were further analyzed after
stratification according to baseline kidney function (i.e.,
eGFR < 60ml/min/1.73m2 or ≥ 60ml/min/1.73m2). P




The baseline characteristics of the patients are shown in
Table 1. The study included 20,686 patients (52.5% male),
with a mean age of 59 years. Patients were split into quar-
tiles according to serum phosphorus levels: first quartile,
< 2.9 mg/dl; second quartile, 2.9–3.4mg/dl; third quartile,
3.5–3.8mg/dl; and fourth quartile, > 3.8 mg/dl. Patients in
the first quartile were older at baseline and included more
males compared with the other groups. More patients in
the fourth quartile were diagnosed with hypertension, but
there was no difference in history of cardiovascular disease
among the groups. Patients in the lower quartiles tended
to have lower cholesterol and higher eGFR levels. The
mean follow-up period was 3.6 ± 1.2 years.
Association between serum phosphorus and renal
outcome
AKI occurred in 2321 (11.2%) patients after hospital ad-
mission, with prevalence of 10.6, 8.8, 9.2, and 16.6% in
the first to fourth quartiles, respectively. Non-linear rela-
tionship analysis demonstrated an exponential relation-
ship between serum phosphorus and the risk of AKI
Table 3 Risk of end-stage renal disease according to serum phosphorus level
Total eGFR < 60 ml/min/1.73 m2 eGFR ≥60 ml/min/1.73 m2
Groups HR (95% CI) P HR (95% CI) P HR (95% CI) P
Q1 1 (reference) 1 (reference) 1 (reference)
Q2 0.95 (0.609–2.077) 0.871 0.99 (0.464–2.095) 0.971 0.94 (0.323–2.736) 0.910
Q3 1.45 (1.342–4.015) 0.185 0.83 (0.399–1.712) 0.608 2.74 (1.110–6.748) 0.029
Q4 2.34 (1.462–3.750) < 0.001 1.17 (0.654–2.100) 0.595 5.25 (2.361–11.659) < 0.001
eGFR estimated glomerular filtration rate, HR hazard ratio, CI confidence interval
Fig. 3 Kaplan–Meier curves for all-cause mortality according to quartiles of serum phosphorus
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(Fig. 1). Logistic regression analysis showed a U-shaped
relationship between phosphate and AKI (ORs: 0.82
[0.720–0.924] in the second quartile, P = 0.001; 0.85
[0.744–0.969] in the third quartile, P = 0.015; 1.68
[1.499–1.881] in the fourth quartile, P < 0.001). The
positive relationship between phosphate level and risk of
AKI remained consistent after adjusting for multiple co-
variates (Table 2), indicating that the trend was not
dependent on reduced kidney function.
Sixty-three patients (0.3%) progressed to ESRD status
based on kidney function during the follow-up period.
The prevalence of ESRD were 0.2, 0.1, 0.3, and 0.8% in the
first to fourth quartile groups, respectively. Kaplan–Meier
curves for ESRD-free survival rates indicated the highest
risk of ESRD in the fourth quartile group (Fig. 2). The HR
for the risk of ESRD was 2.34 (1.462–3.750) in the fourth
quartile group compared with the first quartile group
(Table 3). The HR for ESRD remained higher in the fourth
compared with the first quartile group after adjusting for
multiple covariates, but this trend was only significant in
patients with an eGFR > 60ml/min/1.73m2.
As a sensitivity analysis, we divided patients into three
groups such as low (< 2.5mg/dl), normal (2.5–4.5mg/dl),
and high phosphorus (> 4.5 mg/dl) groups, based on the
reference range. Nevertheless, the risks of AKI and ESRD
were higher in high phosphorus group than in the normal
group, wherein adjusted OR and HR were 6.12 (5.187–
7.209) (P < 0.001) and 1.91 (1.311–2.777) (P = 0.001), re-
spectively. The low group was not associated with the risk
of AKI or ESRD (Ps > 0.05).
Association between phosphorus and mortality
The all-cause mortality rates were 19.8, 16.9, 15.7, and
18.3% in the first to fourth quartile groups, respectively,
and the Kaplan–Meier survival curves showed similar
trends (Fig. 3). Univariate analysis showed that the HRs
for mortality were lower in the second and third quartile
groups (0.83 [0.761–0.904], P < 0.001 and 0.77 [0.702–
0.848], P < 0.001, respectively) compared with the first
quartile group. The mortality rates did not differ be-
tween the first and fourth quartile groups. However, the
mortality risk tended to be higher in the higher quartiles
compared with the first quartile group after adjusting for
multiple covariates (Table 4). Subgroup analysis revealed
positive correlations between serum phosphorus level
and risk of mortality in both CKD and non-CKD groups.
Although a sensitivity analysis was performed, the high
phosphorus group, and not the low phosphorus group,
had a higher risk of mortality than the normal group
with adjusted HR of 1.54 (1.357–1.755) (P < 0.001).
Discussion
Hyperphosphatemia has received considerable attention
in the field of CKD - mineral and bone disorder (CKD-
MBD) because of its association with cardiovascular
morbidity and mortality [3, 6, 16]. Even upper-normal
serum phosphate levels could exacerbate the status of
CKD, potentially leading to ESRD [17]. Based on these
features, this study addressed the relationships between
hyperphosphatemia and the risks of AKI, ESRD, and
mortality among hospitalized patients, and showed that
hyperphosphatemia was significantly associated to
poorer renal outcomes, irrespective of baseline kidney
function.
In addition to patients with CKD-MBD, some studies
have examined the relationship between serum phos-
phorus and morbidity or mortality, particularly in critic-
ally ill patients. Patients admitted to the emergency
department with serum phosphorus levels > 4.5 mg/dl
showed high 28-day in-hospital mortality [18]. Further-
more, higher time-weighted phosphorus levels (i.e., area
under the curve divided by total time between first and
last phosphorus levels) were related to mortality risk in
patients with mechanical ventilation [19]. Hyperpho-
sphatemia was also shown to affect the risk of mortality
in patients undergoing continuous renal replacement
therapy [20]. However, the relevance of hyperphosphate-
mia among heterogeneous patients admitted to the hos-
pital remains unclear. Furthermore, AKI and ESRD have
rarely been considered as the primary outcomes in pre-
vious studies [21].
In the current study, we examined the relationships be-
tween hyperphosphatemia and renal outcomes and mor-
tality in both eGFR < 60ml/min/1.73m2 and ≥ 60ml/min/
1.73m2 groups, to highlight the dangers of high phos-
phorus levels irrespective of kidney function. Hyperpho-
sphatemia induced calcification of smooth muscle cells in
Table 4 Risk of all-cause mortality according to serum phosphorus level
Total eGFR < 60ml/min/1.73m2 eGFR ≥60 ml/min/1.73 m2
Groups HR (95% CI) P HR (95% CI) P HR (95% CI) P
Q1 1 (reference) 1 (reference) 1 (reference)
Q2 1.10 (1.002–1.207) 0.052 1.00 (0.761–1.309) 0.987 1.11 (1.008–1.230) 0.034
Q3 1.16 (1.043–1.281) 0.006 1.28 (0.976–1.691) 0.075 1.14 (1.019–1.272) 0.022
Q4 1.35 (1.221–1.486) < 0.001 1.37 (1.064–1.770) 0.015 1.34 (1.199–1.487) < 0.001
eGFR estimated glomerular filtration rate, HR hazard ratio, CI confidence interval
Moon et al. BMC Nephrology          (2019) 20:362 Page 5 of 7
an in vitro system [22], linked to phenotypic changes from
vascular smooth muscle cells to osteochondrogenic-like
cells [22]. Vascular calcification suggests an increased risk
of cardiovascular events and mortality in patients with
hyperphosphatemia. Some studies also found that high
phosphate intake disrupted endothelial function and thus
affected maintenance of the glomerular filtration barrier
[17–19, 23–25]. This impaired vasodilatation is known to
be dependent on nitric oxide [18, 25]. The Ramipril Effi-
cacy In Nephropathy (REIN) study conducted in patients
with non-diabetic chronic nephropathies found that a 1
mg/dl increase in serum phosphate level was associated
with a 85% excess risk of progression to ESRD [25, 26],
possibly associated with high secretion of fibroblast
growth factor 23 [25]. Following docking of fibroblast
growth factor, the respective receptor increases the pro-
duction of angiotensin-converting enzyme, which may in
turn activate the renin–angiotensin system, potentially fa-
cilitating the onset and progression of kidney damage in
high-risk individuals [26]. Hyperphosphatemia also in-
duced inflammation in vascular smooth muscle cells and
increased the expression of matrix metalloproteinases II
and IX and cathepsin S [9, 27]. These mechanisms may
explain the finding that high concentrations of phos-
phorus affected renal outcomes, as well as mortality.
The strengths of this study included the large number of
hospitalized patients analyzed and its lack of focus on crit-
ically ill patients or patients with CKD alone. Nevertheless,
the study had some limitations. The retrospective design
meant that the causality and mechanism could not be de-
termined. However, this did not affect the primary pur-
pose of the study to determine the relationship between
serum phosphorus and renal outcomes. Unidentified fac-
tors may also have affected or interacted with the present
relationships. We did not investigate the cause of death,
which also limited our understanding of the underlying
mechanisms. Because of relatively small number of pa-
tients with CKD, further studies are needed to assess non-
significant results such as ESRD progression in CKD
subset.
Conclusion
Hyperphosphatemia is associated to the risks of AKI,
ESRD, and mortality among hospitalized patients. Ac-
cordingly, serum phosphorus monitoring may help to
identify patients at high risk of kidney function deterior-
ation or mortality. Further studies are needed to explore
the mechanisms underlying the present observations.
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